Amylyx Pharmaceuticals, Inc.
AMLX
$17.79
$0.352.01%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/24/2026
-
MarketBeat
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?
6/27/2026
-
Simply Wall St
6/27/2026
-
Tickeron - Stocks
Amylyx Pharmaceuticals (AMLX) Reports Early LUMINA Safety Data, Is The Stock Still Below Fair Value?
6/26/2026
-
Simply Wall St
6/26/2026
-
Tickeron - Stocks
6/25/2026
-
The Cerbat Gem
6/24/2026
-
Tickeron - Stocks
6/24/2026
-
Tickeron - Stocks
6/24/2026
-
Tickeron - Stocks
6/23/2026
-
GuruFocus
6/23/2026
-
Business Wire
6/18/2026
-
Tickeron - Stocks
6/12/2026
-
Simply Wall St
6/10/2026
-
The Cerbat Gem
6/10/2026
-
MarketBeat
6/10/2026
-
Seeking Alpha: Transcripts
6/10/2026
-
SeekingAlpha
6/8/2026
-
Simply Wall St
6/8/2026
-
GuruFocus
6/8/2026
-
Business Wire
6/8/2026
-
Globe Newswire
6/5/2026
-
Zacks Investment Research
6/3/2026
-
TipRanks Financial Blog
6/3/2026
-
Zacks Investment Research
5/14/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 682 0917
Address
55 Cambridge Parkway
Cambridge, MA 02142
Cambridge, MA 02142
Country
Year Founded
Business Description
Sector
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the...
more